Avalo Therapeutics, Inc. Common Stock
N/A
USD
N/A
N/A
...
Chart
Financials
Description
AVTX Company Description
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
AVTX Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view AVTX Smart Score
Score Breakdown
AVTX Company Description
Show More
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). Show Less
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of AVTX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by AVTX's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
WallStreetBets
Number of mentions of AVTX in WallStreetBets Daily Discussion
AVTX News
Recent insights relating to AVTX
CNBC Recommendations
Recent picks made for AVTX stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in AVTX
Corporate Flights
Flights by private jets registered to AVTX
Our Analysis